HWPC(SH:688799) Zheng Quan Zhi Xing·2025-06-11 13:13Core Viewpoint - The company plans to adjust and postpone certain sub-projects within its fundraising investment project for drug research and development, while maintaining the total investment amount for the "Drug Research and Development Project" unchanged [1][2][3] Fundraising Investment Project Overview - The company raised a total of RMB 724.27 million by issuing 23.5 million shares at RMB 30.82 per share, with a net amount of RMB 655.65 million after deducting related expenses [1][2] - As of May 31, 2025, the cumulative investment from the raised funds amounted to RMB 408.36 million [2] Adjustments and Postponements - The adjustments involve reallocating unspent funds from completed projects to ongoing or new projects, optimizing the priority of funding based on market conditions and research progress [4][5] - The company aims to enhance the efficiency of fund usage while ensuring that the total investment in the "Drug Research and Development Project" remains unchanged [3][4] Specific Adjustments - Funds from completed projects such as "Compound Polyethylene Glycol Electrolyte Powder" and others will be redirected to ongoing projects like "Qianqing Granules" and new investment projects [5][6] - The company will extend the research timelines for projects like "Qianqing Granules" and "L-Carnitine Oral Solution" to the end of 2028, adjusting funding allocations accordingly [6][8] Research and Development Focus - The company continues to focus on projects in the digestive, respiratory, and anti-infection fields, while also expanding into pain relief, cardiovascular, neurological, and lymphatic treatment areas [8][9] - A total of RMB 47.6 million is allocated for respiratory products, and RMB 47.8 million for pain relief products, among other therapeutic areas [9][10][12] Feasibility Analysis - The company's drug research capabilities and a strong core research team support the ongoing implementation of projects, ensuring a robust pipeline for future product development [15][16] - The adjustments are made to align with market demands and the company's strategic planning, without negatively impacting normal operations or shareholder interests [17][18]